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There were three (5.4%) groin access site complications. There was one death in the first 
30 days of follow-up. This El-year-old man was readmitted with pneumonia on day 13, 
developed ARDS and died on day 26. At 30 days there ware no new neurologic events, 
and the deficits of the two patients with minor strokes post-procedure had resolved. 
Conclusion: Elderly patients were excluded from the NASCET trial due to a high risk of 
complications. Other groups have reported event rates of 19.2% in this age group for 
CAS. Our prospective database shows that CAS can be safely performed in patients 
over 60 years old and represents an attractive alternative to carobd endarterectomy. 
1129-176 Three-Year Clinical and Quantitative Angiographic 
Follow-Up After Carotid Artery Stenting 
Keita Odashira Hiroyoshi Yokoi, Katsumi Inoue, Masashi Iwabuchi, Takeshi Kimura, 
Hideyuki Nosaka, Masakiyo Nobuyoshi, Kokura Memorial Hospital, Kitakyushu. Japan 
Background: Carotid artery stenting (CAS) has evolved as a potential alternative to 
carotid endarlerectomy. However there was little angiographic follow-up data for patients 
receiving stems at extracranial carotid arteries. The purpose of this study was to assess 
the long-term safety and efficacy of CAS. Methods: Out of 31 patients with 36 lesions 
undergoing 6 months follow-up angiography, l-2 years follow-up angicgraphy was avail- 
able in 17 patients with 24 lesions and 3-4 years follow-up angiography was available in 
6 patients with 10 lesions. Quantitative angiographic analysis was performed. Minimal 
luminal diameter(MLD), interpolated referense diameter and % diameter stenosis were 
measured. Stem sites were divided into 10 segments. At each segments, minimal diame- 
ter and mean diameter were measured. External carotid artery patency were examined 
at bifurcation lesions which were covered with stents. Results: At stenotic segments 
greater than 50% before CAS, neointimal hyperplasia became greater than other seg- 
ments at 6 months. Follow-up angiography of 19 lesions at 6 months and 1-2 years 
revealed a decrease in MLD from 4.41*0.55mm immediately after stent implantation to 
3.45+0.39mm at 6 months. but no further decrease in diameter after 6 months (in 
patients with paired angiograms, 3.4520.39mm at 6 months and 3.76+0.3mm at 112 
“ears: P=O.O15). Luminal diameter stabilization was observed at 3-4 veals (in oatients 
I  .  
with paired angiograms, 3.65*0.76mm at 6 months and 4.OOkO.53 mm at 3-4 years; 
P=O.O85). At bifurcation lesions covered by stents, external carotid artery were all patent 
at follow-up angiography. There were no neurologic events associated stented sites dur- 
ing follow-up period. Conclusions: Anglographic and clinlcal outcomes up to 3 years after 
CAS were favorable, with a very low restenotic rate. Stabilization of neointimal hyperpla- 
spa appears to occur after 6 months. 
1129-177 Factor V Leiden Mutation Is Associated With Increased 
Risk for Periprocedural Neurological Deficits in Carotid 
Stenting 
Sabine Steiner, Andrea Bartok, Florian Frommelt, Erich Minx, Christoph W. Kopp, 
University of Vienna, Vienna, Austria 
Background: Factor V Leaden (factor V Arg506Gln). the genetic defect underlying resis- 
tance to activated protein C, is the most important hereditary cause of venous throm- 
boembolism. However, the potential role in arterial thrombosis and disease is still 
controversial. We questioned if patients heterozygous for the mutation are at increased 
risk for periprocedural neurological deficits (PND) during carotid stenting (CS) due to 
impaired control of thrombogenesis. 
Methods: APC resistance (APC-R) ratio was prospectively quantitated in a consecutive 
series of 137 patients who underwent CS for asymptomatic (n=l06) or symptomatic 
(n=31) high-degree (>90%) cervical internal carotid arteiy stenosis. All patients with 
reduced APC-R ware genotyped for factor V Leiden mutation. Occurence of neurological 
deficit within 46 hours after the procedure was recorded and logistic regression analysis 
performed to test the infbence of demographic and clinical factors as well as factor V 
Leiden on PND. 
Results: Patients suffering PND (n=lZ; 6.6%) were similar with respect to cardiovascular 
risk profile compared to total population.(see table) However, in five out of six patients 
who were heterozygous for factor V Leiden’mutation. neurological ischemic complica- 
tions occured with high statistical significance in uni- and multivariate analy- 
sis.(pcO.OOl)Conclusion: Factor V Leaden mutation was identified as an independent risk 
factor for periintelventional neurological deficits in CS. 
Frequencies of Periprocedural Neurologxxd Deficits according to Pment Characteristics 
Variable 
Age, mean&D 
Men, N(%) 
Women. N(%) 
BMI. mean&D 
Symptomatic Carotid Stenosis.N(%) 
Coronary Artery Disease, N(%) 
Claudication. N(%) 
Diabetes mellitus. N(%) 
Hypercholest- 
erolemia. N(%) 
Hypertension, N(%) 
Smoking, N(%) 
Factor V Leaden Mutation, N(%) 
All Patients 
N=l37 
70.6+9.1 
96 (70%) 
41 (30%) 
26.64.6 
31 (23%) 
75 (55%) 
60 (44%) 
46 (35%) 
1 IO (80%) 
102 (75%) 
35 (26%) 
6 (4.4%) 
PND Patients P 
N=l2 
71.0+7.7 n.s. 
8 (67%) “.S. 
4 (33%) n.s. 
24.6+3.2 n.s. 
5 (42%) “.s. 
4 (33%) n.s. 
5 (42%) n.s. 
3 (25%) n.s. 
10 (63%) “.s. 
6 (67%) n.s. 
2 (17%) “.S. 
5 (42%) <O.OOl 
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1129-197 Carotid Stenting With Intravenous Abciximab Is a Safe 
and Efficacious Strategy Compared With Carotid 
Endarterectomy 
Fernando Boccalandro, Edward Baptista. Andreas Muench. Catherine Carter, Morgan 
Campbell, Richard W. Smalling. University of Texas Houston Medical School, Houston, 
TX 
Beckground:The histopathologic analysis of embolized debris collected in distal protec- 
tion devices during carobd artery stenting (CAS) has shown predominantly thrombotic 
material, foam cells and cholesterol emboli. The use of Abciximab a potent platelet glyco- 
protein Ilb/llla receptor inhibitor, has shown to reduce the risk of ischemic events associ- 
ated with coronary interventions and can potentially inhibit the thrombatic component of 
distal emboli described during CAS. The objective of this study is to evaluate the safety 
and effectiveness of the use of Abciximab during carotid stenting compared with carotid 
endarterectomy (CAE). Methods:Abciximab was intravenously administered as a single 
bolus (0.25 mg/kg) and then via infusion (10 mglmin) for 12 hours following CAS in 54 
patients (31 males, 65+12 Yr). In-hospital and 30-day outcomes was compared with 55 
patients undergoing elective CAE (27 males, 76+10). In addition, bleeding complications 
were also recorded. Bleeding complications were classified as major (hemoglobin 
decrease ~5 gidL) or minor (hemoglobin decrease < 5g/dL).Results: NO significant dif- 
ferences wars observed between the demographic characteristics of both groups. 
In-Hospital and 30.day Outcomes & Complications 
In Hospital 
TIA 
Stroke 
Death 
Myocardlal Infarction 
30-Days 
Carotid Stenting Carotid Endarterectomy P Value 
2 (3.7%) 3 (5.4%) 0.671 
1(1.9%) 2(3.6%) 0.561 
2(3.7%) 1(1.6%) 0.549 
0 1(1.6%) 0.321 
TIA 1(1.9%) 1(1.6%) 0.975 
Stroke 0 1(1.6%) 0.321 
Death 0 0 1 
Myocardial Infarction 1(1.9%) 0 0.306 
Major Bleeding 4(7.4%) 3(5.4%) 0.670 
Minor Bleeding 4(7.4%) 2(3.6%) 0.391 
Hospital Stay (Days) 1.4io.7 2.5+1.5 < 0.01 
Conclusion: 
Outcomes of carotid artery stenting plus adjuvant Abciximab are comparable with elec- 
tive CAE, although CAE was associated with a shorter hospital stay. The use of Abcix- 
imab during carotid stenting was not associated with increased risk of bleeding when 
compared with CAE. 
1129-196 Comparison of the Safety and Efficacy of the Use of 
Emboli Protection Device Versus Glycoprotein llblllla 
Inhibitor During Carotid Stenting 
Albert W. Ghan, Deepak L. Bhatt, Christopher T. Bajzer, Eric J. Topol, Jay S. Yadav, 
Ochsner Clinic Foundation, New Orleans, LA, The Cleveland Clinic Foundation, 
Cleveland, OH 
Background: Distal embolizabon constitutes the main potential risk of carotid stenting, 
and techniques to minimize this risk are evolving. Platelet glycoprotein llblllla inhibitors 
(GPI) have been used to reduce the consequences of distal embolization. Recently, 
emboli-protection devices (EPD) have become available and we compared the outcomes 
of these two strategies. 
Methods: Between 0711996 and 03/2002, GPI was used during elective or urgent percu- 
taneous carotid intervention until lOI2000, and EPD was introduced since 07l2000. Fol- 
low-up data ware prospectively collected at 30 days after procedures. Patients who 
received both GPI and EPD were excluded. 
Results: A total of 305 consecutive patients underwent the procedure (199 patients 
received adjunctive GPI [91% abciximab] and 106 patients had EPD [65% filter design, 
15% occlusive balloon]). Compared with GPI, EPD was associated with a trend of lower 
incidence of composite endpoints of neurological death, non-fatal stroke, and intracranial 
hemorrhage, and a significantly lower mcldence of major bleeding (Table). Overall, the 
composite endpoints of neurological death, non-fatal stroke, major bleeding, including 
intracranial hemorrhage, was significantly less frequent with EPD than with GPI. 
Conclusions: EPD may provide an overall safer and more effective means of neuropro- 
tection during carotid stenting as compared with GPI. 
